Neurogen's NGD 91-3 misses Phase IIa endpoint

NRGN said its NGD 91-3 GABA modulator to treat generalized anxiety showed a trend toward patient improvement but did not show statistical significance on the primary endpoint of Hamilton Anxiety scale...